CA2075366A1 - Immunologically active peptides or polypeptides from the parvovirus b19 - Google Patents

Immunologically active peptides or polypeptides from the parvovirus b19

Info

Publication number
CA2075366A1
CA2075366A1 CA002075366A CA2075366A CA2075366A1 CA 2075366 A1 CA2075366 A1 CA 2075366A1 CA 002075366 A CA002075366 A CA 002075366A CA 2075366 A CA2075366 A CA 2075366A CA 2075366 A1 CA2075366 A1 CA 2075366A1
Authority
CA
Canada
Prior art keywords
genetic engineering
parvovirus
antigens
produced
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002075366A
Other languages
French (fr)
Other versions
CA2075366C (en
Inventor
Erwin Soutschek
Manfred Motz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIKROGEN MOLEKULARBIOLOGISCHE ENTWICKLUNGS- GmbH
Original Assignee
Erwin Soutschek
Manfred Motz
Mikrogen Molekularbiologische Entwicklungs- Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP1991/000106 external-priority patent/WO1991011895A1/en
Application filed by Erwin Soutschek, Manfred Motz, Mikrogen Molekularbiologische Entwicklungs- Gmbh filed Critical Erwin Soutschek
Publication of CA2075366A1 publication Critical patent/CA2075366A1/en
Application granted granted Critical
Publication of CA2075366C publication Critical patent/CA2075366C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14211—Erythrovirus, e.g. B19 virus
    • C12N2750/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Immunologically active peptides or polypeptides with a partial amino-acid sequence of the capsid proteins VP1 and VP2 of parvovirus B19 which permit tests to be carried out at low cost, sensitively and specifically for the determination of antibodies against human parvovirus B19 are made available. Short peptide sequences which, employed as antigen, serve to identify anti-B19 IgG-positive sera are identified. Furthermore, the production of these peptides using genetic engineering measures is disclosed. Other antigens which are produced by genetic engineering and which can be stably produced in a high yield in E.coli and subsequently purified therefrom are used as additional antigens for IgG detection. Finally, a set of antigens permits tests to be carried out to determine IgM antibodies against the virus.
In addition, the components, produced by genetic engineering, of the surface proteins represent substances which can be used for prophylactic immunisation.
CA002075366A 1990-02-08 1991-02-08 Immunologically active peptides or polypeptides from the parvovirus b19 Expired - Lifetime CA2075366C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4003826A DE4003826C2 (en) 1990-02-08 1990-02-08 Peptides of the capsid proteins VP1 or VP2 of the parvovirus B19
DEP4003826.2 1990-02-08
PCT/EP1991/000106 WO1991011895A1 (en) 1990-01-29 1991-01-21 Holder for the application of microwave fields to items to be treated

Publications (2)

Publication Number Publication Date
CA2075366A1 true CA2075366A1 (en) 1991-08-09
CA2075366C CA2075366C (en) 2003-02-18

Family

ID=6399718

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002075366A Expired - Lifetime CA2075366C (en) 1990-02-08 1991-02-08 Immunologically active peptides or polypeptides from the parvovirus b19

Country Status (9)

Country Link
EP (1) EP0514413B1 (en)
JP (2) JP3061196B2 (en)
AT (1) ATE105303T1 (en)
AU (1) AU650864B2 (en)
CA (1) CA2075366C (en)
DE (2) DE4003826C2 (en)
DK (1) DK0514413T3 (en)
ES (1) ES2052370T3 (en)
WO (1) WO1991012269A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3149116B2 (en) * 1992-10-28 2001-03-26 信越化学工業株式会社 Epitope-related peptide of human parvovirus
ATE174929T1 (en) * 1993-01-23 1999-01-15 Inmunologia & Genetica Aplic SYNTHETIC PEPTIDES AND VACCINES AGAINST PARVOVIRUS
ATE188746T1 (en) * 1993-10-28 2000-01-15 Deutsches Krebsforsch ADENO-ASSOCIATED VIRUS - ITS DIAGNOSTIC APPLICATION FOR EARLY ABORTION
WO1996027799A1 (en) * 1995-03-08 1996-09-12 Klaus Hedman Method for the diagnosis of infections
JPH0910000A (en) 1995-06-26 1997-01-14 Nippon Sekijiyuujishiya Detection of human parvovirus and reagent therefor
FR2771751B1 (en) 1997-12-03 2000-05-26 Assist Publ Hopitaux De Paris ERYTHROVIRUS AND ITS APPLICATIONS
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6818612B2 (en) 1998-11-24 2004-11-16 Kristina Broliden Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
US6743772B1 (en) 1998-11-24 2004-06-01 Kristina Broliden Use of parovirus capsid particles in the inhibition of cell proliferation and migration
CZ308201B6 (en) 2001-06-28 2020-02-26 Grifols Worldwide Operations Limited Diagnostic tests for parvovirus B19
EP1421095B1 (en) 2001-08-31 2013-10-09 Gen-Probe Incorporated Assay for detection of human parvovirus b19 nucleic acid
WO2007096199A2 (en) * 2006-02-22 2007-08-30 Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh Differential diagnostics and therapy of virally induced heart muscle disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7966987A (en) * 1986-09-08 1988-04-07 Applied Biotechnology, Inc. Empty viral capsid vaccines
DE3939470A1 (en) * 1989-11-29 1991-06-06 Biochrom Beteiligungs Gmbh & C Diagnosis and prevention of human parvovirus B19 infection - using synthetic penta- and higher peptide(s) and antibodies

Also Published As

Publication number Publication date
ES2052370T3 (en) 1994-07-01
DE59101577D1 (en) 1994-06-09
ATE105303T1 (en) 1994-05-15
JP2000184889A (en) 2000-07-04
DK0514413T3 (en) 1994-06-06
JP3061196B2 (en) 2000-07-10
AU650864B2 (en) 1994-07-07
AU7211591A (en) 1991-09-03
WO1991012269A1 (en) 1991-08-22
DE4003826C2 (en) 1995-11-23
EP0514413A1 (en) 1992-11-25
JPH05504143A (en) 1993-07-01
CA2075366C (en) 2003-02-18
DE4003826A1 (en) 1991-08-14
JP3130024B2 (en) 2001-01-31
EP0514413B1 (en) 1994-05-04

Similar Documents

Publication Publication Date Title
Dietzschold et al. Chemical and immunological analysis of the rabies soluble glycoprotein
WO1991015516A3 (en) Hepatitis c virus epitopes
KR960703136A (en) Tandem Synthetic HIV-1 Peptides
KR970010925B1 (en) Hcv peptide - antigens and a method of testing for the hepatitis c virus(hcv)
RU94024561A (en) IMMUNORACTIVE COMPOSITIONS, METHOD FOR PREPARING THE COMPOSITION, METHODS FOR OBTAINING AND DETECTING ANTIBODIES, DNA SET, HOST CELL, METHOD OF OBTAINING PROTEIN
CA2295691A1 (en) Methods and compositions for impairing multiplication of hiv-1
CA2036463A1 (en) Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
CA2047792A1 (en) Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
CA2078694A1 (en) Hepatitis b vaccine
CA2075366A1 (en) Immunologically active peptides or polypeptides from the parvovirus b19
WO1994006913A3 (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
FI964605A0 (en) Hepatitis-G virus and its molecular cloning
US4483793A (en) Dimeric oligopeptides as heptenic epitopic sites for hepatitis
EP0904378A1 (en) Hepatitis b monoclonal antibodies
AU4439993A (en) HCV peptide antigens and method of determining HCV
WO1996010580A3 (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
Joisson et al. Detection of potyviruses with antisera to synthetic peptides
EP0227604A2 (en) Use of oligopeptides in the treatment of viral infections
JPH05230097A (en) Synthetic peptide derived from hbc antigen of hepatitis b virus and use of said peptide for detection of infection with such virus and for antihepatitis b vaccine
Crescenzi et al. Synthetic peptides in diagnosis of plum pox potyvirus
RU92004487A (en) DNA, POLIPEPTID, VACCINE, VECTOR, MICROORGANISM, INSECTED CELL, REAGENT, METHODS OF TREATMENT AND PREVENTION, METHOD OF DETECTING ANTIGENES
PT97428A (en) Process for the preparation of epitopes of the hepatitis C virus

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry